Vimta Labs

Vimta Labs reported a strong Q4 FY26 with total income reaching INR1,120 million, marking a 16.55% YoY increase. EBITDA for the quarter stood at INR421 million, up 21.33% YoY, with an EBITDA margin of 37.6%. For the full fiscal year 2026, total income grew 19.55% YoY to INR4,163 million, and EBITDA increased by 17.98% YoY to INR1,489 million, maintaining a healthy 35.8% margin. PAT for FY26 was INR775 million, a 16.01% YoY growth, with a PAT margin of 18.6% and basic EPS of INR17.4.

FY26 marked a strategic milestone with the company's entry into biologics contract research and development services. Management confirmed that processes, systems, equipment, and people are in place for this new venture. While it is too early to expect significant revenue contribution in its maiden year, the focus for FY27 is to build market traction, onboard a few good clients, and deliver well. Initial margins for this segment are expected to be similar to the company's overall margins, with potential for improvement as the business scales and gains overseas clients.

The company highlighted favorable industry trends, including tightening quality norms, increasing regulatory scrutiny, and innovation in pharmaceuticals and allied industries. Outsourcing in contract research and testing across pharmaceuticals, nutraceuticals, medical devices, electronics, and food continues to be a primary growth driver. Management sees good visibility for food, pharma, and electronics testing, with these industries expected to flourish due to their essential nature and increasing R&D spending.

Vimta Labs maintained a very healthy EBITDA margin of 35.8% for FY26, which is among the best in the industry. Management acknowledged potential fluctuations due to capacity ramp-ups, maintenance costs, people investments, and geopolitical issues. While input material costs and lead times have seen a slight increase due to global events, the company aims to sustain margins in a stable and competitive range over the medium term^⏳, expecting some correction of 1-2% but overall maintenance.

The company has completed its expansion project, with new facilities now operational. The strategy behind this expansion was to create capacity sufficient for growth over the next four to five years. Management expects utilization of these new facilities to pick up gradually, increasing over the current year and subsequent years, aligning with their long-term growth plans.

Vimta Labs maintains a strong financial position with a net debt-free balance sheet and cash and cash equivalents of approximately INR650 million. While the company has sufficient liquidity, management stated there are no firmed-up thoughts on specific capital deployment plans for this cash, such as acquisitions or significant new capacity expansions, beyond the current operational needs. They emphasized the benefit of having cash on hand during uncertain times.

The electronics and electrical testing segment experienced a less exciting year in FY26 due to leadership challenges, which have now been addressed. Management is optimistic about seeing strong movement and improved performance in this segment going forward^⏳. The 'Atmanirbhar' initiative in India and focus on indigenization, particularly in defense, are expected to provide a healthy environment for growth in this sector.